Anthropic Sets Up Bay Area Wet Lab as AI Drug Push Expands

Anthropic has established a wet laboratory in the San Francisco Bay Area, moving its artificial-intelligence ambitions deeper into drug science and beyond purely computational biology, two people familiar with the matter said.

The company's head of life sciences, Eric Kauderer-Abrams, confirmed the facility in an interview, saying that real lab work remains the decisive test in biology. He described Anthropic's approach as resembling that of most biotech firms, with some experiments conducted in its own facilities and others handled through external partners. A spokesperson later said the lab is not intended specifically for drug discovery, without elaborating.

The effort is a modest step toward Anthropic's broader goal of addressing diseases it believes the pharmaceutical industry has neglected. The startup also wants to advance how its Claude AI can direct robotic units to run experiments with limited human intervention, one person said. Anthropic maintains that human oversight remains essential for safety.

"We're in the very early innings of using AI to automate the execution of lab work," Kauderer-Abrams said, describing the area as having the potential to accelerate many processes.

The work is unfolding at a charged moment. In the past two weeks, some Anthropic researchers warned that AI could lead to human extinction, and the company said it found instances where its systems could have been used for biological weapons development, a finding that drew some skepticism. Chief Executive Dario Amodei has also called for a development slowdown, even as the company prepares for a potentially massive initial public offering.

"In our life-science work, we're always balancing these things," Kauderer-Abrams said, citing efforts to improve models that could uplift medicine development while deploying them carefully to limit risk.

Anthropic signalled its drug-program ambitions at a San Francisco event in June, where Kauderer-Abrams said the company would pursue preclinical work in areas traditional firms find financially unattractive. It has launched software called Claude Science, added Novartis CEO Vas Narasimhan to its board, and acquired the startup Coefficient Bio for about $400 million in stock, according to media reports. Anthropic confirmed the acquisition but declined to comment on the price.

The company is expanding its in-house lab efforts for speed and firsthand biological experience, while outsourcing when efficient. "There's some things that we can do much faster in our own hands," Kauderer-Abrams said, with the aim of operating at the largest possible scale.

Recent job postings point to a procurement ramp-up, a search for expertise in protein and nucleic acid characterization, and a stated goal of speeding life-sciences progress by an order of magnitude. Life sciences is already among Anthropic's largest investment areas by headcount and resources, Kauderer-Abrams said.

He believes AI could fast-track development for conditions once considered "undruggable," including complex bispecific and trispecific antibodies that can target multiple points on a protein or cell. The specific diseases Anthropic is pursuing and its progress remain unclear, and bringing a molecule to market typically takes years of human testing — a challenge the company has not taken on. Rival Alphabet's drug-discovery arm, Isomorphic Labs, has worked for years toward the clinic and earlier pushed that goal to the end of 2026.

Anthropic launched the Model Hardware Standard in August to help AI operate equipment, and it supplies such tools and broader AI services to pharmaceutical companies including Roche's Genentech, Bristol Myers Squibb and Novo Nordisk. At the same time, it faces a trust problem, the two people said, as customers may worry Anthropic could learn from their competing drug programs even though the startup walls off their data.

Kauderer-Abrams said Anthropic has set a boundary against running clinical trials for now, partly due to competition concerns, and is focusing on needs industry would not address. "We're not competing with pharma and biotech companies that make their business in bringing drugs to market," he said.